Fredun Pharmaceuticals (539730) investor relations material

Executive summary

• Standalone total income for Q1 FY 2027 reached INR 228.25 crores, up 90.44% year-over-year, with EBITDA at INR 32.78 crores, up 92.90% year-over-year, and net profit at INR 13.17 crores, up 94.63% year-over-year.

• Unaudited financial results for the quarter ended 30 June 2026 were reviewed and approved by the Board on 5 August 2026.

• Both standalone and consolidated results were prepared in accordance with Ind AS and reviewed by statutory auditors with unmodified conclusions.

Financial highlights

• Q1 FY 2027 standalone total income: INR 228.25 crores (+90.44% YoY); EBITDA: INR 32.78 crores (+92.90% YoY); net profit: INR 13.17 crores (+94.63% YoY).

• Standalone revenue from operations for the quarter was ₹22,775.55 lakhs, up from ₹11,940.29 lakhs year-over-year.

• Standalone net profit for the quarter was ₹1,316.81 lakhs, compared to ₹676.58 lakhs in the same quarter last year.

• Basic EPS for the quarter was ₹23.89, up from ₹14.33 year-over-year.

• EBIT margin improved to 9%-10% in Q1, with expectations to reach 12%-13% over the next 12 quarters.

Outlook and guidance

• Blended revenue growth of 30%-35% expected for the next three years, driven by both new and vintage brands, capacity expansion, and product portfolio additions.

• Pet Care and Gx businesses expected to grow 30%-50% annually for the next three to five years, with significant market potential due to low pharma penetration.

• Revenue target for FY 2027 is around INR 800 crores, with the company on track to overachieve.

• Results were reviewed and recommended by the Audit Committee and approved by the Board, indicating continued compliance and operational stability.